CLYM Climb Bio, Inc.
Climb Bio, Inc. (CLYM) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $471.0K.
Where they traded
Last open-market purchase: January 5, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Brennan Aoife | President and CEO | Sell 10b5-1 | 30,902 | $13.17 | $407.0K | 87,731 −26% of holding | |
| Thomas Stephen Basil | Director | Sell 10b5-1 | 16,313 | $7.01 | $114.3K | 154,657 −9.5% of holding | |
| Thomas Stephen Basil | Director | Sell 10b5-1 | 33,687 | $7.00 | $236.0K | 170,970 −16.5% of holding | |
| Thomas Stephen Basil | Director | Sell 10b5-1 | 10,000 | $5.81 | $58.1K | 204,657 −4.7% of holding | |
| Thomas Stephen Basil | Director | Sell 10b5-1 | 90,000 | $5.23 | $471.0K | 214,657 −29.5% of holding | |
| Buy | 7,111 | $3.50 | $24.9K | 3,403,429 | |||
| Buy | 101,462 | $2.86 | $290.2K | 3,396,318 | |||
| Buy | 213,099 | $2.18 | $464.6K | 3,294,856 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.